The inaugural study in Elizabethtown, Kentucky, served as the testing ground for the modular Eidos Prism, an add-on designed to upgrade existing 3D mammography systems. With data collection complete, investigators have submitted two peer-reviewed manuscripts detailing the technology's diagnostic performance, with publication expected later this year. Dr. Craig Kamen, who led the clinical application, noted the efficiency of the collaboration in navigating the complexities of patient research.
In section Releases
Calidar Concludes First Human Trial of 4D Mammography Device
Following the successful closure of a 61-patient study at Baptist Health Hardin, Calidar is transitioning its Eidos Prism technology toward a multi-site pivotal trial. The device, which utilizes Volumetric X-Ray Diffraction to provide molecular-level imaging, is now being positioned for a broader clinical rollout by 2027.
Calidar is currently vetting potential locations for its 2027 pivotal study, aiming to diversify its patient cohort. The company is scouting five to seven sites across four U.S. regions, targeting a mix of rural health systems, academic medical centers, and independent imaging clinics. By analyzing the molecular fingerprint of breast tissue, the company seeks to provide diagnostic clarity that standard 3D imaging currently lacks.
Comments (0)
No comments yet. Be the first!